Archives: Agenda
Enhancing the patient journey in oncology trials: Patient insights and practical innovation
- Considering the full patient burden landscape when planning oncology clinical trials to alleviate patient burden effectively
- Recognizing disparities in burden and understanding differences across patient populations
- Incorporating patient input when designing protocols to ensure that needs are met
From Tension to Trust: Aligning Medical monitoring and Clinical Operations in Complex Oncology Trials
- Cultural and behavioral dynamics
- Differing incentives and pressures
- Communication failures during safety events
- Building trust under time pressure
Analyzing patient adherence to drug therapy effectively: A practical guide to methods and metrics for increased efficiency in oncology drug trials
- Definition, Importance and Measurement of adherence
- Key adherence methods and matrix
- Increasing efficiency of adherence through enhancement and implementation
Lunch and networking
WORKSHOP: Responsible AI in oncology clinical trials: Applying the AI rights initiative to recruitment, patient data, and patient trust
Concept: This interactive workshop introduces the AI Rights Initiative as a practical framework that sponsors, CROs, and recruitment vendors can use to evaluate AI systems used in oncology trials. Through a short panel discussion and facilitated table conversations, participants will explore how recruitment algorithms, digital tracking technologies, and patient data analytics intersect with patient rights and regulatory responsibilities
Takeaway: Attendees will leave with practical governance questions that can help organizations implement AI responsibly while maintaining patient trust in clinical research
END OF DAY 1 AND NETWORKING DRINKS
Signal Over Sprawl: Using Adaptive Randomization to Focus Early Oncology Development
Adaptive randomization can help conserve scarce patient data by increasing learning efficiency in early oncology trials. Its value depends on sponsors entering development with clear priorities around one or two target indications. Without that discipline, adaptive designs risk adding operational complexity to broad, unfocused programs without yielding a clean development signal. This presentation will explore adaptive randomization and its utility in:
- Conserving scarce patient data in early development
- Improving signal detection through intentional focus
- Rewarding discipline over broad exploratory ambition
Overview of the investor landscape to navigate and secure investment for oncology clinical trials
- Aligning clinical trials with today’s investment priorities
- Building investor value: From inflection points to unique positioning
- Strategic connections for oncology clinical trial funding